252 related articles for article (PubMed ID: 22237842)
1. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.
Essler M; Gärtner FC; Neff F; Blechert B; Senekowitsch-Schmidtke R; Bruchertseifer F; Morgenstern A; Seidl C
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):602-12. PubMed ID: 22237842
[TBL] [Abstract][Full Text] [Related]
2. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells.
Drecoll E; Gaertner FC; Miederer M; Blechert B; Vallon M; Müller JM; Alke A; Seidl C; Bruchertseifer F; Morgenstern A; Senekowitsch-Schmidtke R; Essler M
PLoS One; 2009 May; 4(5):e5715. PubMed ID: 19479088
[TBL] [Abstract][Full Text] [Related]
3. Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest.
Vallon M; Seidl C; Blechert B; Li Z; Gilbertz KP; Baumgart A; Aichler M; Feuchtinger A; Gaertner FC; Bruchertseifer F; Morgenstern A; Walch AK; Senekowitsch-Schmidtke R; Essler M
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1886-97. PubMed ID: 22872310
[TBL] [Abstract][Full Text] [Related]
4. 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.
Seidl C; Zöckler C; Beck R; Quintanilla-Martinez L; Bruchertseifer F; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2011 Feb; 38(2):312-22. PubMed ID: 21072513
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of HER2-Targeted Intraperitoneal
Chung SK; Vargas DB; Chandler CS; Katugampola S; Veach DR; McDevitt MR; Seo SH; Vaughn BA; Rinne SS; Punzalan B; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Yang G; Ouerfelli O; Nash GM; Cercek A; Fung EK; Howell RW; Larson SM; Cheal SM; Cheung NV
J Nucl Med; 2023 Sep; 64(9):1439-1445. PubMed ID: 37348919
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
[TBL] [Abstract][Full Text] [Related]
7.
Pfannkuchen N; Bausbacher N; Pektor S; Miederer M; Rosch F
Curr Radiopharm; 2018; 11(3):223-230. PubMed ID: 29866026
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
Song H; Hobbs RF; Vajravelu R; Huso DL; Esaias C; Apostolidis C; Morgenstern A; Sgouros G
Cancer Res; 2009 Dec; 69(23):8941-8. PubMed ID: 19920193
[TBL] [Abstract][Full Text] [Related]
9. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Bidkar AP; Wang S; Bobba KN; Chan E; Bidlingmaier S; Egusa EA; Peter R; Ali U; Meher N; Wadhwa A; Dhrona S; Dasari C; Beckford-Vera D; Su Y; Tang R; Zhang L; He J; Wilson DM; Aggarwal R; VanBrocklin HF; Seo Y; Chou J; Liu B; Flavell RR
Clin Cancer Res; 2023 May; 29(10):1916-1928. PubMed ID: 36917693
[TBL] [Abstract][Full Text] [Related]
11. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of targeted alpha therapy with
Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Królicki B; Jakuciński M; Pawlak D; Apostolidis C; Mirzadeh S; Rola R; Merlo A; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):614-622. PubMed ID: 30498897
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Knör S; Sato S; Huber T; Morgenstern A; Bruchertseifer F; Schmitt M; Kessler H; Senekowitsch-Schmidtke R; Magdolen V; Seidl C
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):53-64. PubMed ID: 17891393
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.
Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963
[TBL] [Abstract][Full Text] [Related]
15. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.
Buchhorn HM; Seidl C; Beck R; Saur D; Apostolidis C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):841-9. PubMed ID: 17206415
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes.
Wilson JJ; Ferrier M; Radchenko V; Maassen JR; Engle JW; Batista ER; Martin RL; Nortier FM; Fassbender ME; John KD; Birnbaum ER
Nucl Med Biol; 2015 May; 42(5):428-438. PubMed ID: 25684650
[TBL] [Abstract][Full Text] [Related]
18. Supply and Clinical Application of Actinium-225 and Bismuth-213.
Morgenstern A; Apostolidis C; Bruchertseifer F
Semin Nucl Med; 2020 Mar; 50(2):119-123. PubMed ID: 32172796
[TBL] [Abstract][Full Text] [Related]
19. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
[TBL] [Abstract][Full Text] [Related]
20. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
Morgenstern A; Bruchertseifer F; Apostolidis C
Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]